Sunday, 20 September 2026European Markets

TERACT Stock Bullish By 18% In The Last 5 Sessions

Loading stream...

(vianews) - shares of teract (cac 40: tract.pa) rose by a staggering 18.36% in 5 sessions from 6.1 € to 7.22 € at 22:13 est on wednesday, after five successive sessions in a row of gains. cac 40 is sliding 0.18% to 7,119.83 €, after two sequential sessions in a row of losses.

about teract

teract s.a. operates in retail business in europe. the company operates through garden centre retailer and marketer segments. it operates garden centers and pet care shops under the jardiland, gamm vert, delbard, and jardinerie du terroir brand names. the company also operates in the fresh, local, and organic produce sector under frais d'ici and bio&co brands with food outlets. it operates 1,597 stores. the company is based in paris, france.

volume

today's last reported volume for teract is 3369 which is 90.77% above its average volume of 1766.

more news about teract (tract.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com